VANCOUVER, BC, /PRNewswire/ - Defense Metals Corp. ("Defense Metals" or the "Company") (TSXV: DEFN) (OTCQB: DFMTF) (FSE: 35D), a company ...
Namodenoson is a highly selective A3 adenosine receptor (A3AR) agonist, which has shown a compelling safety profile and demonstrated anti-tumor activity in preclinical pancreatic cancer models. The ...
Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule ...
Q4 2025 Earnings Call March 2, 2026 4:30 PM ESTCompany ParticipantsRobert DeVitaDavid Hung - Founder, President, CEO ...
"Table Mountain represents a rare, discovery-stage opportunity in Nevada: a district-scale low-sulphidation epithermal system that appears exceptionally well preserved at surface and has no known ...
A new analysis dives into why Europe’s eye clinics lag on biosimilars and how education, guidance, and smarter tenders could unlock €747 million in savings.
Because such statements deal with future events and are subject to many risks and uncertainties, actual results may differ materially from those in the forward-looking statements. Joining me on ...
The federal Consolidated Appropriations Act of 2026 (CAA 2026) and recent regulatory developments could potentially ...
We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up for any (or all) of our 25+ Newsletters. Some states have laws and ethical rules regarding solicitation and ...
PRAME Cell Therapy: Global, randomized, controlled Phase 3 trial, SUPRAME, in previously treated advanced melanoma ongoing; anzu-cel received Orphan Drug Designation from the FDA for the treatment of ...
Assay results from recent rock and soil sampling have outlined a newly developing large-scale gold-copper system at West Wing, as detailed in this announcement. Further results from 2025 soil and rock ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results